MMR/MSI在Ⅱ/Ⅲ期结直肠癌辅助化疗中的应用进展
|
摘要
微卫星稳定性作为评价DNA错配修复系统(MMR)的功能标记,可作为Ⅱ期和Ⅲ期结直肠癌患者辅助治疗的风险评估有效工具。全文从错配修复基因/微卫星不稳定性与结直肠癌发生及其在Ⅱ/Ⅲ期结肠癌化疗辅助治疗中的应用方面进行综述。
Stability of microsatellite as a functional marker for evaluation of DNA mismatch repair(MMR) system,was used as an effective tool for the risk evaluation of adjuvant treatment of patients with colorectal cancer stage Ⅱ and Ⅲ. The correlation between MMR/MSI and colorectal cancer,and the application of MMR/MSI in adjuvant chemotherapy for colorectal cancer stage Ⅱ/Ⅲ were reviewed.
Stability of microsatellite as a functional marker for evaluation of DNA mismatch repair(MMR) system,was used as an effective tool for the risk evaluation of adjuvant treatment of patients with colorectal cancer stage Ⅱ and Ⅲ. The correlation between MMR/MSI and colorectal cancer,and the application of MMR/MSI in adjuvant chemotherapy for colorectal cancer stage Ⅱ/Ⅲ were reviewed.
引文
[1]Yu XB,Wang HJ,Sun ZQ,et al.Mismatch repair gene protein expression and clinical significance in patients with sporadic colorectal carcinoma[J].Chinese General Practice,2014,17(8):883-887.[于显博,王海江,孙振强,等.散发性结直肠癌患者错配修复基因蛋白表达水平及其临床意义[J].中国全科医学,2014,17(8):883-887.]
[2]Markowitz SD,Bertagnolli MM.Molecular origin of cancer:molecular basis of colorectal cancer[J].N Engl J Med,2009,361(25):2449-2460.
[3]Cao W,Zhang CL.Advances in the research of microsatellite instability in human gastric cancer[J].Chin J Bases Clin General Surg,2013,20(7):826-833.[曹伟,张长乐.胃癌微卫星不稳定研究进展[J].中国普外基础与临床杂志,2013,20(7):826-833.]
[4]Fu Y,Du XY.Research progress in microsatellite instability in cancer[J].Journal of Oncology,2012,18(1):64-66.[付煜,杜小燕.微卫星不稳定性与肿瘤的研究进展[J].肿瘤学杂志,2012,18(1):64-66.]
[5]Li XO,Li CL,Zhang HW,et al.The clinical significances of concomitant colonoscopies in hereditary non-polyposis colorectal cancer family members with MMR gene mutation[J].The Journal of Practical Medicine,2013,29(14):2279-2280.[李晓鸥,李成林,张宏文,等.对HNPCC家系中MMR基因突变携带者结肠镜随访监测的临床意义[J].实用医学杂志,2013,29(14):2279-2280.]
[6]Gulimil BYT,Yu L,Shi XL,et al.Expressions of mismatch repair gene(MMR)proteins in atypical endometrial hyperplasi[J].Journal of Xinjiang Medical University,2014,37(10):1301-1304.[古丽米拉·巴依坦,余丽,师晓莉,等.错配修复基因(MMR)蛋白在子宫内膜非典型增生中的表达及其意义[J].新疆医科大学学报,2014,37(10):1301-1304.]
[7]Chen T,Yan L.Expression of mismatch repair genes h MLH1 and h MSH2 and their significance in patients with colorectal carcinoma[J].China Journal Clinical Oncology,2013,40(12):710-712.[陈涛,严立.错配修复基因h MSH2和h MLH1在结直肠癌组织中的表达及临床意义[J].中国肿瘤临床,2013,40(12):710-712.]
[8]Tan SK,Yu HP,Wang ZG,et al.Study on the relationship between mismatch repair system MLH1 polymorphisms and hepatocellular carcinoma[J].Chinese Journal of Disease Control&Prevention,2014,18(5):401-404.[谭盛葵,余红平,王志刚,等.错配修复系统MLH1基因rs1800734多态性与肝细胞癌的关联研究[J].中华疾病控制杂志,2014,18(5):401-404.]
[9]Liu R,Shou T,Zhou LK,et al.Research progress of microsatellite instability’s judging prognosis and response to chemotherapy in colorectal cancer[J].China Journal Clinical Oncology,2013,40(4):239-242.[刘锐,寿涛,周礼鲲,等.微卫星不稳定性判断结直肠癌预后和预测化疗疗效相关研究进展[J].中国肿瘤临床,2013,40(4):239-242.]
[10]Song YT,Zhou XY,Sun CS,et al.Expression of h MLH1,h MSH2 in salivary gland mucoepidermoid carcinoma[J].Progress in Modern Biomedicine,2014,14(10):1839-1843.[宋颖韬,周晓燕,孙长生,等.错配修复蛋白h MSH2、h MLH1在涎腺粘液表皮样癌中的表达[J].现代生物医学进展,2014,14(10):1839-1843.]
[11]Qin Q.Prognostic and predictive roles of DNA mismatch repair status in stageⅡ/EI colon cancer and multivariate cox analysis of prognostic factors after radical resection[D].Beijing:Peking Union Medical College and Chinese academy of Medical Sciences,2013.[秦琼.Ⅱ、Ⅲ期结肠癌根治术后复发转移多因素分析及DNA错配修复(MMR)蛋白状态对预后和疗效预测的影响[D].北京:北京协和医学院中国医学科学院,2013.]
[12]Zhang MZ,Zhang W.Expression of mismatch repair gene h MLH1 and h MSH2 in colorectal carcinoma and its significance[J].China Cancer,2013,22(4):308-311.[张苗尊,章维.错配修复基因h MSH2和h MLH1在结直肠癌组织中的表达及意义[J].中国肿瘤,2013,22(4):308-311.]
[13]Wright DM,Arnold JL,Parry B,et al.Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young a patients:the 7-year auckland experience[J].Dis Colon Rectum,2011,54(5):552-558.
[14]Kim GP,Colangelo LH,Wieand HS,et al.Prognostic and predictive roles of high-degree Microsatellite instability in colon cancer:a national cancer institute-national surgical adjuvant breast and bowel project collaborative study[J].J Clin Oncol,2007,25(7):767-772.
[15]Sinicrope FA,Foster NR,Thibodeau SN,et al.DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J].J Natl Cancer Inst,2011,101(11):863-875.
[16]Hutchins G,Southward K,Handley K,et al.Value of mismatch repair,KRAS,and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer[J].J Clin Oncol,2011,29(10):1261-1270.
[17]Tournigand C,AndréT,Bonnetain F,et al.Adjuvant therapy with fluorouracil and oxaliplatin in stageⅡand elderly patients(between ages 70 and 75 years)with colon cancer:subgroup analyses of the multicenter international study of Oxaliplatin,fluorouracil,and leucovorin in the adjuvant treatment of colon cancer trial[J].J Clin Oncol,2012,30(27):3353-3360.
[18]AndréT,Boni C,Navarro M,et al.Improve overall survival with oxaliplatin,fluorouracil,and leucovorin as adjuvant treatment in stageⅡorⅢcolon cancer in the MOSAIC trial[J].J Clin Oncol,2009,27(19):3109-3116.
[19]Kim ST,Lee J,Park SH,et al.The effect of DNA mismatch repair(MMR)status on oxaliplatinbased first-line chemotherapy as in recurrent or metastatic colon cancer[J].Medical Oncology,2010,27(4):1277-1285.
[20]Sinicrope FA,Mahoney MR,Smyrk TC,et al.Prognostic impact of deficient DNA mismatch repair in patients with stageⅢcolon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy[J].J Clin Oncol,2013,31(29):3664-3672.
[21]Bertagnolli MM,Niedzwiecki D,Compton CC,et al.Microsatellite instability predicts improved response to adjuvant therapy with irinotecan,fluorouracil,and leucovorin in stageⅢcolon cancer:cancer and leukemia group B protocol 89803[J].J Clin Oncol,2009,27(11):1814-1821.
[22]Ma JZ,Du YJ,Ce J,et al.The prognosis relationship of Microsatellite instability(MSI)and colorectal cancer[J].Family Psychological Doctor,2014,(8):128.[马继周,杜勇军,撤俊,等.微卫星不稳定(MSI)与结直癌发病及预后的关系[J].家庭心理医生,2014,(8):128.]
[2]Markowitz SD,Bertagnolli MM.Molecular origin of cancer:molecular basis of colorectal cancer[J].N Engl J Med,2009,361(25):2449-2460.
[3]Cao W,Zhang CL.Advances in the research of microsatellite instability in human gastric cancer[J].Chin J Bases Clin General Surg,2013,20(7):826-833.[曹伟,张长乐.胃癌微卫星不稳定研究进展[J].中国普外基础与临床杂志,2013,20(7):826-833.]
[4]Fu Y,Du XY.Research progress in microsatellite instability in cancer[J].Journal of Oncology,2012,18(1):64-66.[付煜,杜小燕.微卫星不稳定性与肿瘤的研究进展[J].肿瘤学杂志,2012,18(1):64-66.]
[5]Li XO,Li CL,Zhang HW,et al.The clinical significances of concomitant colonoscopies in hereditary non-polyposis colorectal cancer family members with MMR gene mutation[J].The Journal of Practical Medicine,2013,29(14):2279-2280.[李晓鸥,李成林,张宏文,等.对HNPCC家系中MMR基因突变携带者结肠镜随访监测的临床意义[J].实用医学杂志,2013,29(14):2279-2280.]
[6]Gulimil BYT,Yu L,Shi XL,et al.Expressions of mismatch repair gene(MMR)proteins in atypical endometrial hyperplasi[J].Journal of Xinjiang Medical University,2014,37(10):1301-1304.[古丽米拉·巴依坦,余丽,师晓莉,等.错配修复基因(MMR)蛋白在子宫内膜非典型增生中的表达及其意义[J].新疆医科大学学报,2014,37(10):1301-1304.]
[7]Chen T,Yan L.Expression of mismatch repair genes h MLH1 and h MSH2 and their significance in patients with colorectal carcinoma[J].China Journal Clinical Oncology,2013,40(12):710-712.[陈涛,严立.错配修复基因h MSH2和h MLH1在结直肠癌组织中的表达及临床意义[J].中国肿瘤临床,2013,40(12):710-712.]
[8]Tan SK,Yu HP,Wang ZG,et al.Study on the relationship between mismatch repair system MLH1 polymorphisms and hepatocellular carcinoma[J].Chinese Journal of Disease Control&Prevention,2014,18(5):401-404.[谭盛葵,余红平,王志刚,等.错配修复系统MLH1基因rs1800734多态性与肝细胞癌的关联研究[J].中华疾病控制杂志,2014,18(5):401-404.]
[9]Liu R,Shou T,Zhou LK,et al.Research progress of microsatellite instability’s judging prognosis and response to chemotherapy in colorectal cancer[J].China Journal Clinical Oncology,2013,40(4):239-242.[刘锐,寿涛,周礼鲲,等.微卫星不稳定性判断结直肠癌预后和预测化疗疗效相关研究进展[J].中国肿瘤临床,2013,40(4):239-242.]
[10]Song YT,Zhou XY,Sun CS,et al.Expression of h MLH1,h MSH2 in salivary gland mucoepidermoid carcinoma[J].Progress in Modern Biomedicine,2014,14(10):1839-1843.[宋颖韬,周晓燕,孙长生,等.错配修复蛋白h MSH2、h MLH1在涎腺粘液表皮样癌中的表达[J].现代生物医学进展,2014,14(10):1839-1843.]
[11]Qin Q.Prognostic and predictive roles of DNA mismatch repair status in stageⅡ/EI colon cancer and multivariate cox analysis of prognostic factors after radical resection[D].Beijing:Peking Union Medical College and Chinese academy of Medical Sciences,2013.[秦琼.Ⅱ、Ⅲ期结肠癌根治术后复发转移多因素分析及DNA错配修复(MMR)蛋白状态对预后和疗效预测的影响[D].北京:北京协和医学院中国医学科学院,2013.]
[12]Zhang MZ,Zhang W.Expression of mismatch repair gene h MLH1 and h MSH2 in colorectal carcinoma and its significance[J].China Cancer,2013,22(4):308-311.[张苗尊,章维.错配修复基因h MSH2和h MLH1在结直肠癌组织中的表达及意义[J].中国肿瘤,2013,22(4):308-311.]
[13]Wright DM,Arnold JL,Parry B,et al.Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young a patients:the 7-year auckland experience[J].Dis Colon Rectum,2011,54(5):552-558.
[14]Kim GP,Colangelo LH,Wieand HS,et al.Prognostic and predictive roles of high-degree Microsatellite instability in colon cancer:a national cancer institute-national surgical adjuvant breast and bowel project collaborative study[J].J Clin Oncol,2007,25(7):767-772.
[15]Sinicrope FA,Foster NR,Thibodeau SN,et al.DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J].J Natl Cancer Inst,2011,101(11):863-875.
[16]Hutchins G,Southward K,Handley K,et al.Value of mismatch repair,KRAS,and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer[J].J Clin Oncol,2011,29(10):1261-1270.
[17]Tournigand C,AndréT,Bonnetain F,et al.Adjuvant therapy with fluorouracil and oxaliplatin in stageⅡand elderly patients(between ages 70 and 75 years)with colon cancer:subgroup analyses of the multicenter international study of Oxaliplatin,fluorouracil,and leucovorin in the adjuvant treatment of colon cancer trial[J].J Clin Oncol,2012,30(27):3353-3360.
[18]AndréT,Boni C,Navarro M,et al.Improve overall survival with oxaliplatin,fluorouracil,and leucovorin as adjuvant treatment in stageⅡorⅢcolon cancer in the MOSAIC trial[J].J Clin Oncol,2009,27(19):3109-3116.
[19]Kim ST,Lee J,Park SH,et al.The effect of DNA mismatch repair(MMR)status on oxaliplatinbased first-line chemotherapy as in recurrent or metastatic colon cancer[J].Medical Oncology,2010,27(4):1277-1285.
[20]Sinicrope FA,Mahoney MR,Smyrk TC,et al.Prognostic impact of deficient DNA mismatch repair in patients with stageⅢcolon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy[J].J Clin Oncol,2013,31(29):3664-3672.
[21]Bertagnolli MM,Niedzwiecki D,Compton CC,et al.Microsatellite instability predicts improved response to adjuvant therapy with irinotecan,fluorouracil,and leucovorin in stageⅢcolon cancer:cancer and leukemia group B protocol 89803[J].J Clin Oncol,2009,27(11):1814-1821.
[22]Ma JZ,Du YJ,Ce J,et al.The prognosis relationship of Microsatellite instability(MSI)and colorectal cancer[J].Family Psychological Doctor,2014,(8):128.[马继周,杜勇军,撤俊,等.微卫星不稳定(MSI)与结直癌发病及预后的关系[J].家庭心理医生,2014,(8):128.]